- Home
- Industries
Aerospace And Defence
Agriculture
Automotive And Transportation
Banking And Finance
Business
Chemicals And Materials
Consumer And Retail
Electronics And Semiconductors
Food And Beverages
Machinery & Equipments
Manufacturing And Construction
Medical Devices
Others
Pharmaceuticals And Healthcare
Power And Energy
Sports
Technology
- Services
- News Room
- About us
- Contact Us
-
Global Spatial Genomics Market Size, Share & Forecast | CAGR 17.4%
Global Spatial Genomics Market Size, Share, Analysis By Technology (Spatial Transcriptomics, Spatial Genomics, Sequencing-Based Methods, Imaging-Based Approaches, In-Situ Sequencing, In-Situ Hybridization FISH, In-Situ Capture), By Product (Instruments, Consumables, Software & Services), By Sample Type (FFPE Tissue, Fresh-Frozen Tissue, Organoids & 3D Cell Cultures), By Application (Oncology, Neurology, Immunology, Drug Discovery), By End-User (Pharma, Biotech, Academia, CROs) Region & Key Players-Dynamics, Strategies & Forecast 2026-2034
Report Overview
| Market Size (2025) | Forecast Value (2034) | CAGR (2026-2034) | Largest Region (2025) |
| USD 0.57 Billion | USD 2.42 Billion | 17.4% | North America, 42.8% |
The Spatial Genomics Market was valued at USD 0.48 Billion in 2024 and USD 0.57 Billion in 2025. The market is projected to reach USD 2.42 Billion by 2034, expanding at a CAGR of 17.4% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 1.85 Billion over the analysis period.
Spatial Genomics Market Global Forecast to 2034 (USD)
CAGR OF
17.4%
Spatial Genomics Market
Get more details on this report -
The spatial genomics market is advancing because oncology, neuroscience, immunology, and developmental biology buyers now require tissue-context data that bulk RNA sequencing and dissociated single-cell workflows cannot preserve. 10x Genomics disclosed USD 144.0 Million in 2025 spatial consumables revenue, up 19% year over year, while its installed spatial base reached 1,015 Visium instruments and 554 Xenium instruments at year-end 2025. Bruker Corporation expanded CosMx Spatial Molecular Imager capabilities in February 2026 with miRNA, TCR, and mouse whole-transcriptome programs, reinforcing multi-analyte tissue profiling as a core commercial battleground.
Regulation shapes clinical translation rather than basic discovery. The U.S. Food and Drug Administration reverted its laboratory-developed-test rule language in September 2025 after the March 2025 court vacatur, which returned clinical spatial assay commercialization to a CLIA, CAP, and state-laboratory oversight model in the United States. The European Union In Vitro Diagnostic Regulation keeps pressure on clinical-grade spatial assays by requiring analytical performance files, specimen controls, software validation, and post-market surveillance for tests used in patient care.
Technical differentiation moved from slide imaging alone to plex count, tissue thickness, sample throughput, and software interpretation. 10x Genomics introduced Atera in April 2026 with 18,000 protein-coding gene targets and optional 1,000-gene custom panels. Singular Genomics launched G4X in the United States in February 2026 with 128 samples per run and a 5-day workflow, while Stellaromics launched Pyxa for 3D spatial transcriptomics in tissue sections up to 100 micrometers thick. These 2026 launches reduce the throughput gap between spatial genomics and conventional sequencing.
North America led the spatial genomics market with 42.8% share in 2025, equal to approximately USD 0.24 Billion, because the United States concentrates 10x Genomics, Vizgen, Singular Genomics, Element Biosciences, NIH-funded cell atlas programs, and large cancer centers. Asia Pacific is forecast to post the fastest regional CAGR at approximately 20.3% through 2034 as China, Japan, Singapore, and South Korea build spatial atlases, translational oncology centers, and domestic genomics supply chains.
Market Definition & Scope
The spatial genomics market is defined as commercial activity surrounding instruments, consumables, reagents, imaging systems, sequencing workflows, software, and services that measure DNA or RNA signals while preserving the physical location of cells inside tissue. The market encompasses spatial transcriptomics, in situ hybridization, in situ sequencing, spatial single-cell genomics, tissue-based gene panels, morphology-linked molecular mapping, and computational cell segmentation used by 10x Genomics, Bruker Corporation, Vizgen, Illumina, Singular Genomics, and Element Biosciences.
This analysis includes sequencing-based slide capture, imaging-based in situ transcriptomics, spatial multiomics products with RNA readouts, sample-preparation kits, analysis pipelines, and contract research services used in oncology, neuroscience, immunology, developmental biology, and drug discovery. It excludes proteomics-only spatial imaging, conventional immunohistochemistry, bulk RNA sequencing, non-spatial single-cell sequencing, qPCR, and microscopy systems without genomic or transcriptomic measurement. The spatial genomics market sits inside the broader spatial biology category, but the scope is limited to RNA and DNA-centered workflows.
Key Takeaways
- Market Growth: The spatial genomics market is estimated at USD 0.57 Billion in 2025 and is forecast to reach USD 2.42 Billion by 2034 at a 17.4% CAGR, producing USD 1.85 Billion in absolute dollar opportunity.
- Segment Dominance: Consumables and reagents led the offering mix with 52.4% share in 2025, equal to approximately USD 0.30 Billion, because each tissue run requires slides, probes, barcoded capture reagents, enzymes, and imaging buffers.
- Segment Dominance: Oncology and tumor microenvironment studies held 39.5% application share in 2025, equal to approximately USD 0.23 Billion, because cancer centers need spatial maps of malignant cells, immune cells, fibroblasts, and therapy-resistance niches.
- Driver: Spatial consumables revenue at 10x Genomics rose 19% in 2025 to USD 144.0 Million, indicating that installed-base usage is expanding faster than instrument purchases.
- Restraint: Instrument capital costs, tissue-processing complexity, and image-analysis bottlenecks keep spatial genomics adoption below conventional RNA sequencing, with high-throughput systems still requiring trained histology, imaging, and bioinformatics teams.
- Opportunity: Population-scale spatial programs represent a USD 0.62 Billion revenue opportunity by 2034, led by tissue atlas projects, colorectal cancer cohorts, brain mapping initiatives, and pharma translational biomarker programs.
- Trend: Whole-transcriptome in situ platforms became the dominant 2026 product theme, with 10x Genomics Atera targeting 18,000 genes and Bruker CosMx expanding to whole-transcriptome spatial biology.
- Regional: North America led with 42.8% share in 2025, equal to approximately USD 0.24 Billion, supported by NIH funding, U.S. cancer centers, and domestic suppliers including 10x Genomics, Vizgen, Singular Genomics, and Element Biosciences.
Key Insights Summary
- 10x Genomics spatial consumables reached USD 144.0 Million in 2025, a 19% year-over-year increase, while cumulative Visium and Xenium placements reached 1,569 instruments across tissue-mapping laboratories.
- The NIH Human BioMolecular Atlas Program Data Portal hosted 5,032 datasets across 22 data types, 27 organ classes, and 310 donors as of October 2025, creating a reference layer for spatial genomics benchmarking.
- Atera from 10x Genomics targets 18,000 protein-coding genes and accepts up to 1,000 custom additions, making whole-transcriptome in situ spatial genomics practical for hypothesis-free tissue discovery.
- Singular Genomics G4X processes up to 128 FFPE tissue samples per run with a 5-day sample-to-answer timeline, lowering per-sample spatial analysis cost for cohort-scale studies.
- Stellaromics Pyxa supports 3D spatial transcriptomics in intact tissue sections from 20 micrometers to more than 100 micrometers, addressing sampling error created by thin 2D sections.
- Bio-Techne reported USD 346.3 Million in fiscal 2025 Diagnostics and Spatial Biology segment revenue, up 6% from fiscal 2024, with RNAscope and COMET supporting RNA-plus-protein tissue workflows.
- Vizgen closed USD 48 Million in financing in January 2026, extending the commercial runway for MERFISH-based MERSCOPE Ultra platforms and software-enabled spatial multiomics adoption.
Competitive Landscape Overview
The spatial genomics market is moderately consolidated, with 10x Genomics, Bruker Corporation, Illumina, and Vizgen forming the top commercial group by installed base, spatial consumables revenue, platform breadth, and disclosed financing. Industry analysis indicates the top four suppliers represented approximately 52% of 2025 commercial activity when platform revenue, in situ chemistry usage, service pull-through, and active customer footprint are combined. Competition is technology-led: 10x Genomics competes on integrated Visium, Xenium, and Atera workflows; Bruker competes through CosMx and GeoMx spatial biology systems; Illumina competes on sequencing-based spatial transcriptomics; Vizgen competes on MERFISH resolution and software depth.
Competitive behavior shifted in 2025-2026 from isolated instruments toward workflow ownership. Quanterix Corporation closed the Akoya Biosciences transaction in July 2025, adding tissue imaging assets to blood biomarker infrastructure. 10x Genomics filed patent suits against Illumina in October 2025, showing that spatial genomics intellectual property now carries strategic weight.
Competitive Landscape Matrix
| Company Name | Headquarters (Country) | Market Position | Key Product/Solution in this market | Geographic Strength | Recent Strategic Move |
| 10x Genomics, Inc. | United States | Leader | Visium HD, Xenium, Atera | North America, Europe, Asia Pacific | Introduced Atera in April 2026 with 18,000-gene in situ coverage and 1,000-target customization. |
| Bruker Corporation | United States | Leader | CosMx SMI, GeoMx DSP, AtoMx SIP | North America, Europe, Japan | Broadened CosMx programs in February 2026 to miRNA, TCR, and mouse whole-transcriptome workflows. |
| Illumina, Inc. | United States | Leader | Sequencing-based spatial transcriptomics program | Global sequencing installed base | Outlined a spatial transcriptomics roadmap in February 2025 with first availability targeted for 2026. |
| Vizgen, Inc. | United States | Leader | MERSCOPE Ultra, MERFISH 2.0 | United States, Europe, Asia Pacific | Secured USD 48 Million financing in January 2026 and added new panels plus AI segmentation in April 2026. |
| Bio-Techne Corporation | United States | Challenger | RNAscope, COMET | North America, Europe, China | Reported USD 346.3 Million fiscal 2025 Diagnostics and Spatial Biology revenue. |
| Takara Bio USA / Curio Bioscience | United States / Japan | Challenger | Curio Seeker and Trekker kits | Japan, United States, Europe | Integrated Curio Bioscience spatial genomics kits into Takara Bio's global channel after the 2025 acquisition. |
| Singular Genomics Systems, Inc. | United States | Challenger | G4X in situ multiomics platform | United States | Started U.S. G4X commercialization in February 2026 with 128-sample runs. |
| Element Biosciences, Inc. | United States | Challenger | AVITI24 Direct In Sample Sequencing | United States, Europe | Surpassed 50 AVITI24 installations in 2025 and advanced tissue multiomics workflows in 2026. |
| Stellaromics, Inc. | United States | Niche Player | Pyxa 3D spatial multiomics | United States, United Kingdom | Launched Pyxa in February 2026 for spatial transcriptomics in tissue sections above 100 micrometers. |
| Resolve Biosciences GmbH | Germany | Niche Player | Molecular Cartography | Europe, North America | Continued commercial deployment of subcellular smFISH-based RNA mapping for translational research. |
Segmentation Analysis
The spatial genomics market segments by offering, technology, application, and end-user, with economics shaped by recurring consumables, tissue throughput, RNA plex count, and bioinformatics intensity. Segment shares are estimated from disclosed spatial revenue, installed-base data, product pricing, academic adoption, and pharma-service utilization.
By Offering
The spatial genomics market by offering is led by consumables and reagents, which accounted for 52.4% of 2025 revenue, equal to approximately USD 0.30 Billion. This category includes Visium slides, Xenium probe sets, CosMx panels, MERFISH reagents, Curio Seeker kits, enzymes, sequencing libraries, imaging buffers, and quality-control materials. Recurring usage creates the most defensible revenue stream because a single high-throughput oncology or atlas program can consume hundreds of tissue slides per quarter. 10x Genomics reported USD 144.0 Million in 2025 spatial consumables revenue, making consumables the clearest disclosed proof point for commercial pull-through. Bruker, Vizgen, Takara Bio, and Bio-Techne compete by expanding validated panel menus and sample compatibility.
Instruments represented 34.1% of 2025 revenue, or approximately USD 0.19 Billion, led by Xenium Analyzer, CosMx SMI, MERSCOPE Ultra, AVITI24, G4X, Pyxa, and COMET. Instrument revenue is more cyclical because buyers often pause capital purchases during NIH budget uncertainty or hospital CAPEX delays. Software and services held 13.5% share, equal to roughly USD 0.08 Billion, but this slice is expanding faster than instruments because tissue segmentation, cell typing, batch correction, and spatial statistics remain bottlenecks.
By Technology
The spatial genomics market by technology is led by sequencing-based spatial capture, which held 41.6% share in 2025, equal to approximately USD 0.24 Billion. Visium HD, Curio Seeker, and Illumina's sequencing-based program use barcoded capture areas or related chemistry to connect transcript reads with tissue coordinates. This approach benefits from existing Illumina, MGI, and AVITI sequencing infrastructure, which reduces switching cost for genomics cores.
Imaging-based in situ transcriptomics held 38.9% share in 2025, or approximately USD 0.22 Billion, through Xenium, CosMx, MERSCOPE, RNAscope, Molecular Cartography, and related hybridization workflows. Imaging-based platforms provide single-cell and subcellular localization with panel sizes ranging from tens to whole-transcriptome coverage depending on vendor and assay. Spatial multiomics and in situ sequencing held the remaining 19.5% share, or approximately USD 0.11 Billion, supported by G4X, AVITI24, Pyxa, COMET, and emerging RNA-plus-protein systems. The technology decision increasingly depends on whether the buyer needs full transcriptome breadth, subcellular localization, sample throughput, 3D context, or compatibility with archived FFPE tissue.
By Application
The spatial genomics market by application is led by oncology and tumor microenvironment analysis, which captured 39.5% share in 2025, or approximately USD 0.23 Billion. Cancer laboratories use spatial genomics to measure immune exclusion, T-cell exhaustion, tertiary lymphoid structures, stromal barriers, hypoxia zones, and therapy-resistant clones inside the same tissue section. 10x Genomics, Bruker, Vizgen, Bio-Techne, and Singular Genomics target this application because pharma sponsors need companion-biomarker evidence before moving spatial assays into clinical trials. The value proposition is strongest when spatial maps explain why a genomically eligible tumor fails to respond to immunotherapy.
Neuroscience and cell atlas programs represented 25.8% share in 2025, or approximately USD 0.15 Billion, supported by HuBMAP, Human Cell Atlas, BICAN, Allen Institute, RIKEN, and European neurobiology centers. Immunology and infectious disease accounted for 16.8% share, or approximately USD 0.10 Billion, as tissue-resolved RNA maps help characterize granulomas, transplant rejection, viral reservoirs, and inflammatory bowel disease. Drug discovery and translational medicine held 17.9% share, or approximately USD 0.10 Billion, with pharma teams using spatial genomics to connect mechanism of action, toxicity, and patient stratification.
By End-User
The spatial genomics market by end-user is led by academic and government research institutions with 47.5% share in 2025, equal to approximately USD 0.27 Billion. NIH, HuBMAP, Human Cell Atlas, Cancer Research UK, RIKEN, AMED, Max Planck institutes, DKFZ, and Chinese Academy of Sciences programs drive demand through atlas projects and investigator-led disease cohorts. Academic buyers prefer open data formats, flexible panels, and publication-grade visualization because spatial datasets often become shared community resources. Research cores also act as reference customers for vendors seeking tissue-protocol validation across FFPE, fresh frozen, organoid, and thick-section samples.
Pharmaceutical and biotechnology companies represented 34.8% share, or approximately USD 0.20 Billion, because spatial genomics can reveal target expression, pathway activation, immune neighborhoods, and safety signals in human tissue. CROs, clinical research organizations, pathology service laboratories, and translational testing providers held 17.7% share, or roughly USD 0.10 Billion. This service channel will expand through 2034 as more sponsors outsource tissue processing, image QC, and spatial bioinformatics.
Regional Analysis
North America led the spatial genomics market with 42.8% share in 2025, equal to approximately USD 0.24 Billion. The United States represented about USD 0.22 Billion of regional demand, while Canada and Mexico contributed roughly USD 0.02 Billion. NIH awarded USD 35.3 Billion in competing and noncompeting grants in fiscal 2025 from a USD 48.5 Billion appropriation, supporting cancer, brain, immunology, and cell atlas programs that buy spatial platforms. Domestic suppliers include 10x Genomics, Vizgen, Singular Genomics, Element Biosciences, Bio-Techne, and Stellaromics. The FDA's 2025 LDT reversion kept clinical spatial assay pathways tied to CLIA, CAP, and state oversight, which gives research-use platforms time to mature before broad diagnostic use.
Europe accounted for 27.1% of the spatial genomics market in 2025, valued at approximately USD 0.15 Billion. Germany, the United Kingdom, France, Switzerland, and the Netherlands are the top contributors, supported by DKFZ, Charite Berlin, EMBL, Wellcome Sanger Institute, ETH Zurich, and Amsterdam UMC. The EU In Vitro Diagnostic Regulation raises documentation requirements for clinical spatial assays, while Horizon Europe and national cancer-mission programs support spatial atlas and biomarker projects. Bruker Corporation, Resolve Biosciences, Miltenyi Biotec, Zeiss, and European sites of 10x Genomics and Vizgen form the supplier base.
Asia Pacific held 24.2% of the spatial genomics market in 2025, equal to approximately USD 0.14 Billion, and is forecast to expand at a 20.3% CAGR through 2034. China, Japan, South Korea, Singapore, and Australia lead regional adoption through cancer centers, brain atlases, translational pathology programs, and domestic genomics platforms. China benefits from BGI, STOmics, MGI sequencing infrastructure, and large hospital biobanks. Japan benefits from Takara Bio's Curio Bioscience integration, RIKEN cell biology programs, and AMED-funded translational research.
Latin America represented 3.7% of the spatial genomics market in 2025, equivalent to approximately USD 0.02 Billion. Brazil, Mexico, Argentina, Chile, and Colombia drive demand through cancer genomics, infectious disease pathology, and academic research cores. Brazil's FAPESP and Fiocruz programs support translational tissue studies, while Mexico's private hospital networks purchase spatial services through distributors rather than direct platform ownership. Regional adoption is limited by instrument import duties, reagent logistics, trained bioinformatics capacity, and lower reimbursement support. Cloud-based analysis and service-lab models will be more practical than local full-platform ownership for many Latin American buyers through 2034.
Middle East and Africa held 2.2% of the spatial genomics market in 2025, equal to approximately USD 0.01 Billion. Israel, Saudi Arabia, the United Arab Emirates, Qatar, and South Africa represent the practical demand base. Saudi Arabia's Vision 2030 life-sciences investments, UAE genomics programs, and Israeli computational biology groups create concentrated pockets of spatial genomics adoption. South African universities use spatial tools in infectious disease and oncology research, but reagent costs and limited local support slow installation rates. Over the forecast period, the region will rely on outsourced spatial genomics services for large cohorts while building domestic tissue-processing capacity.
Country Analysis
The United States spatial genomics market reached approximately USD 0.22 Billion in 2025 and is forecast to grow at a 16.9% country CAGR through 2034. NIH grant spending, HuBMAP, BICAN, NCI cancer centers, and pharma translational medicine teams create the deepest demand base globally. 10x Genomics reported 1,569 cumulative spatial instruments across Visium and Xenium at year-end 2025, while Vizgen, Singular Genomics, Element Biosciences, Stellaromics, Bio-Techne, and Quanterix add domestic platform depth.
China's spatial genomics market reached approximately USD 0.052 Billion in 2025 and is projected to expand at a 21.3% CAGR through 2034. BGI, STOmics, MGI, Westlake University, Chinese Academy of Sciences institutes, and large oncology hospitals support domestic adoption. Demand is tied to cancer mapping, developmental biology, reproductive medicine, and brain research, with local sequencing infrastructure reducing workflow cost. China differs from the United States because domestic suppliers can bundle sequencing, spatial capture, and cloud analysis under national data-governance rules. Buyers still face cross-border reagent sourcing risk for some high-plex imaging workflows.
Germany's spatial genomics market stood at approximately USD 0.045 Billion in 2025, with a country CAGR of 16.4% forecast through 2034. DKFZ, Charite Berlin, Max Delbruck Center, Heidelberg University, EMBL-associated programs, and Bruker-linked European channels anchor demand. German buyers emphasize reproducibility, FFPE validation, and EU IVDR readiness because university hospitals often bridge research and translational pathology. Resolve Biosciences in Germany provides Molecular Cartography, while Bruker Spatial Biology maintains a strong European commercial position through CosMx, GeoMx, AtoMx, and CellScape. Funding remains tied to oncology missions and precision-medicine consortia.
Japan's spatial genomics market reached approximately USD 0.033 Billion in 2025 and is forecast to grow at a 17.2% CAGR through 2034. Takara Bio's Curio Bioscience acquisition added spatial genomics kits to a domestic life-sciences channel serving RIKEN, Kyoto University, University of Tokyo, and AMED-funded programs. Japan's demand centers on oncology, neuroscience, regenerative medicine, and aging biology. PMDA expectations for clinical evidence make diagnostic conversion slower than research adoption, but academic tissue-bank strength favors high-quality FFPE cohorts. Japanese buyers often prioritize local technical support, validated tissue protocols, and integration with existing Illumina or MGI sequencing infrastructure.
Spatial Genomics Market
Size, by Region, 2025-2034 (USD)
The Market will Grow
At the CAGR of:
17.4%
The Forecast Market
Size for 2034 in USD:
$USD 2.42 B
Get more details on this report -
Key Market Segments
By Offering
- Instruments
- Consumables
- Software
- Analytical Services
- Data Analysis Platforms
- Cloud-Based Bioinformatics Solutions
- Others
By Technology
- Spatial Transcriptomics
- Spatial Genomics Sequencing
- In Situ Sequencing
- Fluorescence In Situ Hybridization (FISH)
- Immunohistochemistry (IHC)
- Laser Capture Microdissection (LCM)
- Digital Spatial Profiling (DSP)
- Single-Cell Spatial Genomics
- Others
By Application
- Cancer Research
- Drug Discovery and Development
- Clinical Diagnostics
- Neuroscience Research
- Immunology Research
- Developmental Biology
- Cell Biology Research
- Precision Medicine
- Biomarker Discovery
- Others
By End-User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Hospitals and Diagnostic Laboratories
- Contract Research Organizations (CROs)
- Clinical Research Organizations
- Government Research Organizations
- Biopharmaceutical Companies
- Others
By Regional Coverage
- North America
- Latin America
- East Asia And Pacific
- Sea And South Asia
- Eastern Europe
- Western Europe
- Middle East & Africa
| Report Attribute | Details |
| Market size (2025) | USD 0.57 B |
| Forecast Revenue (2034) | USD 2.42 B |
| CAGR (2025-2034) | 17.4% |
| Historical data | 2021-2024 |
| Base Year For Estimation | 2025 |
| Forecast Period | 2026-2034 |
| Report coverage | Revenue Forecast, Competitive Landscape, Market Dynamics, Growth Factors, Trends and Recent Developments |
| Segments covered | By Offering, (Instruments, Consumables, Software, Analytical Services, Data Analysis Platforms, Cloud-Based Bioinformatics Solutions, Others), By Technology, (Spatial Transcriptomics, Spatial Genomics Sequencing, In Situ Sequencing, Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Laser Capture Microdissection (LCM), Digital Spatial Profiling (DSP), Single-Cell Spatial Genomics, Others), By Application, (Cancer Research, Drug Discovery and Development, Clinical Diagnostics, Neuroscience Research, Immunology Research, Developmental Biology, Cell Biology Research, Precision Medicine, Biomarker Discovery, Others), By End-User, (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Diagnostic Laboratories, Contract Research Organizations (CROs), Clinical Research Organizations, Government Research Organizations, Biopharmaceutical Companies, Others), |
| Research Methodology |
|
| Regional scope |
|
| Competitive Landscape | 10X GENOMICS, INC., BRUKER CORPORATION, ILLUMINA, INC., VIZGEN, INC., BIO-TECHNE CORPORATION, TAKARA BIO USA / CURIO BIOSCIENCE, SINGULAR GENOMICS SYSTEMS, INC., ELEMENT BIOSCIENCES, INC., STELLAROMICS, INC., RESOLVE BIOSCIENCES GMBH, QUANTERIX CORPORATION / AKOYA BIOSCIENCES, RARECYTE, INC., MILTENYI BIOTEC B.V. & CO. KG, STOMICS / BGI GENOMICS, ZEISS GROUP, OTHERS |
| Customization Scope | Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF). |
Frequently Asked Questions
How big is the Spatial Genomics Market?
The Global Spatial Genomics Market was valued at USD 0.48 Billion in 2024 and USD 0.57 Billion in 2025, and is projected to reach USD 2.42 Billion by 2034, growing at a CAGR of 17.4% from 2026 to 2034. Market growth is driven by spatial transcriptomics, precision medicine, and next-generation sequencing technologies.
Who are the major players in the Spatial Genomics Market?
10X GENOMICS, INC., BRUKER CORPORATION, ILLUMINA, INC., VIZGEN, INC., BIO-TECHNE CORPORATION, TAKARA BIO USA / CURIO BIOSCIENCE, SINGULAR GENOMICS SYSTEMS, INC., ELEMENT BIOSCIENCES, INC., STELLAROMICS, INC., RESOLVE BIOSCIENCES GMBH, QUANTERIX CORPORATION / AKOYA BIOSCIENCES, RARECYTE, INC., MILTENYI BIOTEC B.V. & CO. KG, STOMICS / BGI GENOMICS, ZEISS GROUP, OTHERS
Which segments covered the Spatial Genomics Market?
By Offering, (Instruments, Consumables, Software, Analytical Services, Data Analysis Platforms, Cloud-Based Bioinformatics Solutions, Others), By Technology, (Spatial Transcriptomics, Spatial Genomics Sequencing, In Situ Sequencing, Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Laser Capture Microdissection (LCM), Digital Spatial Profiling (DSP), Single-Cell Spatial Genomics, Others), By Application, (Cancer Research, Drug Discovery and Development, Clinical Diagnostics, Neuroscience Research, Immunology Research, Developmental Biology, Cell Biology Research, Precision Medicine, Biomarker Discovery, Others), By End-User, (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Diagnostic Laboratories, Contract Research Organizations (CROs), Clinical Research Organizations, Government Research Organizations, Biopharmaceutical Companies, Others),
How can this market research report help my business make strategic decisions?
Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.
How frequently is the data updated?
We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.
Select Licence Type
Connect with our sales team
Why IntelEvoResearch
100%
Customer
Satisfaction
24x7+
Availability - we are always
there when you need us
200+
Fortune 50 Companies trust
IntelEvoResearch
80%
of our reports are exclusive
and first in the industry
100%
more data
and analysis
1000+
reports published
till date